...
【24h】

Locally advanced tonsillar squamous cell carcinoma: Treatment approach revisited.

机译:局部晚期扁桃体鳞状细胞癌:重新探讨治疗方法。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

AIMS: The purpose of this study was to review the treatment policy for locally advanced stage III and IV squamous cell carcinoma (SCC) of the tonsil at the Princess Alexandra Hospital Head and Neck Unit, Brisbane, Australia. MATERIALS AND METHODS: The records of 148 patients with curable stage III and IV SCC of the tonsil were reviewed from the years 1992 to 2004 inclusive. During this period, patients were treated with surgery and postoperative radiotherapy and only offered definitive radiation if they were medically or surgically inoperable. There were 102 patients treated with surgery +/- postoperative radiotherapy (group 1) and 46 patients treated with definitive radiotherapy +/- chemotherapy (group 2). The endpoints of locoregional control (LRC), disease specific survival (DSS), and overall survival (OS) were studied and prognostic factors were investigated with univariate and multivariate analyses. RESULTS: The 5-year OS, DSS, and LRC were 57%, 69%, and 84%, respectively. Univariate analyses showed that patients in group 1 had a superior OS (69% vs. 41%, P = .007), a trend toward improvement in LRC (88% vs. 73%, P = .08), and a nonsignificant improvement in DSS (75% vs. 56%, P = .14). There was a greater percentage of patients with an Eastern Cooperative Oncology Group (ECOG) score of 2 or less in group 1, suggesting selection bias toward the surgical group. Multivariate analyses, which adjusted for known prognostic factors, showed that treatment group was significant for OS but not for LRC or DSS. CONCLUSIONS: Surgery and postoperative radiotherapy continues to provide a superior outcome in locally advanced tonsil SCC in patients with surgically resectable disease, good ECOG performance status, and medically operable.
机译:目的:本研究的目的是回顾澳大利亚布里斯班公主亚历山大医院头部和颈部单位对扁桃体局部晚期III和IV期鳞状细胞癌(SCC)的治疗策略。材料与方法:回顾性分析了1992年至2004年间148例扁桃体可治愈的III期和IV期SCC患者的病历。在此期间,对患者进行了手术和术后放疗,如果他们在医学或外科手术上无法手术,则只能进行确定性放射治疗。有102例接受手术+/-术后放疗的患者(第1组)和46例接受了明确放疗+/-化疗的患者(第2组)。研究了局部区域控制(LRC),疾病特异性生存(DSS)和总体生存(OS)的终点,并通过单因素和多因素分析研究了预后因素。结果:5年OS,DSS和LRC分别为57%,69%和84%。单因素分析显示,第1组患者的OS较好(69%比41%,P = .007),LRC有改善的趋势(88%vs. 73%,P = .08),且无显着改善在DSS中(75%对56%,P = 0.14)。在第1组中,东部合作肿瘤小组(ECOG)得分为2或更低的患者比例更高,这表明对手术组的选择偏向。对已知的预后因素进行调整的多变量分析显示,治疗组对OS而言很重要,但对LRC或DSS则不重要。结论:对于可手术切除的疾病,良好的ECOG表现状态且可手术治疗的患者,外科手术和术后放疗继续为局部晚期扁桃体SCC提供更好的治疗效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号